Sort
48,018 grants matching “immunotherapy”
Mechanisms of Immune Evasion by Ocular Tumors
$374,963Kyle C McKenna · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · EY
Immunization Strategies for Autologous HIV Immunotherapy
$374,963Louis D Falo · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · AI
Immune Response to Cat: Regulatory and Effector T Cells
$374,963Judith A Woodfolk · University Of Virginia · R01 · FY2010 · AI
Immune activation by cetuximab in head and neck cancer patients
$374,963Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · DE
Immune activation by cetuximab in head and neck cancer patients
$374,963Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2012 · DE
Tracking allergen specific T cells in multi-food allergy
$374,941Kari C. Nadeau · Stanford University · U19 · FY2023 · AI
EPITOPE-SPECIFIC ANTIBODIES FOR ALZHEIMER'S DISEASE
$374,937Boston Biotechnology Corporation · R44 · FY2005 · AG
EPITOPE-SPECIFIC ANTIBODIES FOR ALZHEIMER'S DISEASE
$374,937Boston Biotechnology Corporation · R44 · FY2004 · AG
GHRELIN VACCINES FOR CONTROLLING OBESITY
$374,937Victor A Raso · Boston Biotechnology Corporation · R44 · FY2006 · DK
GHRELIN VACCINES FOR CONTROLLING OBESITY
$374,937Victor A Raso · Boston Biotechnology Corporation · R44 · FY2007 · DK
Role of IL21 in HIV Infection
$374,888Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2011 · AI
Understanding Interleukin-18 Mediated Susceptibility to Systemic Hyperinflammation
$374,865Scott William Canna · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · HD
Understanding Interleukin-18 Mediated Susceptibility to Systemic Hyperinflammation
$374,865Scott William Canna · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · HD
IMMUNOTHERAPY TRIAL IN NEW ONSET TYPE 1 DIABETES
$374,864University Of Colorado Denver · R01 · FY2000 · DK
Antigen-independent prediction and biomarker identification of cancer-specific T cells
$374,864Bo Li · Ut Southwestern Medical Center · R01 · FY2021 · CA
Augmenting Quadruple Negative Breast Cancer Treatment by ADRM1 Inhibitor Up284
$374,850Balasubramanyam Karanam · Tuskegee University · U54 · FY2023 · MD
Sensitizing high grade serous cancers to immunotherapy through the induction of DNA damage
$374,836Karen McLean · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Analysis Of T Cell Receptor Structure And Function
$374,834Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
PRETARGETING WITH ANTI-CEA MABS FOR THERAPY
$374,826Paul Yazaki · Beckman Research Institute/City Of Hope · P01 · FY2011 · CA
Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
$374,823John H Sampson · Duke University · R01 · FY2013 · CA
Molecular Characterization of C. neoformans Antibodies
$374,813Arturo Casadevall · Albert Einstein College Of Medicine · R37 · FY2012 · AI
Molecular Mechanisms Controlling NK Receptors
$374,803Charles T. Lutz · University Of Kentucky · R01 · FY2009 · AI
Inhibitory Pathways Underlying Viral Persistance in vivo
$374,790Elina I Zuniga · University Of California, San Diego · R01 · FY2013 · AI
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices
$374,782Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2019 · CA
Shared Resource: Proteomics & Metabolomics
$374,779Philip Robert Gafken · Fred Hutchinson Cancer Center · P30 · FY2024 · CA